Article info
PDFClinical science
APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration
- Correspondence to Michael N Cohen, Ophthalmic Consultants of Boston, 50, Staniford Street, Suite 600, Boston, MA 02114, USA; mcohen{at}midatlanticretina.com
Citation
APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration
Publication history
- Received April 13, 2020
- Revised May 21, 2020
- Accepted May 29, 2020
- First published June 25, 2020.
Online issue publication
April 22, 2021
Article Versions
- Previous version (22 April 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.